Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543647 | 0.88 | L3MBTL1 (0.42) | L3MBTL1SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL9789988 | 0.86 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL2910041 | 0.79 | L3MBTL3 (0.31) | L3MBTL1L3MBTL3 | |
| SCHEMBL736051 | 0.75 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL10412770 | 0.74 | — | — | |
| SCHEMBL9687115 | 0.74 | HPGD (0.33) | SMN1; SMN2HPGD | |
| SCHEMBL7008001 | 0.73 | — | — | |
| SCHEMBL7369318 | 0.71 | CYP2D6 (0.31) | — | |
| SCHEMBL18404028 | 0.71 | L3MBTL1 (0.42) | L3MBTL1SMN1; SMN2CYP2A13ALDH1A1HPGD | |
| SCHEMBL738007 | 0.70 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2CYP2A13ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-115974673-A | Novel synthesis method of loxoprofen acid | 上海奥萝拉医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4148045-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B] INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3378854-B1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| CN-108558740-B | S1P1 receptor modulators and salts thereof | 艾尼纳制药公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3847158-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-2569319-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-20 | — | — | EP | disclosed |
| CN-102884065-A | Heteroaryl-cyclohexyl-tetraazabenzo [ e ] azulenes | HOFFMANN LA ROCHE | 2013-01-16 | — | — | CN | disclosed |
| EP-2528894-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012136772-A1 | FUSED PYRROLE DERIVATES AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-10-11 | — | — | WO | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| WO-2011141396-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | S1PR1, S1PR5, S1PR3 | L3MBTL1 4489/4885SMN1; SMN2 3313/4885CYP2A13 1524/4885 |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | L3MBTL1 2818/4885SMN1; SMN2 4091/4885CYP2A13 1739/4885 |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | L3MBTL1 4489/4885SMN1; SMN2 3313/4885CYP2A13 1524/4885 |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | L3MBTL1 2818/4885SMN1; SMN2 4091/4885CYP2A13 1739/4885 |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | L3MBTL1 2849/4885SMN1; SMN2 4085/4885CYP2A13 1744/4885 |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | L3MBTL1 2818/4885SMN1; SMN2 4091/4885CYP2A13 1739/4885 |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | L3MBTL1 4357/4885SMN1; SMN2 3953/4885CYP2A13 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.